| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
|
N Engl J Med
|
2004
|
4.84
|
|
2
|
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
|
J Clin Oncol
|
2006
|
3.50
|
|
3
|
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
|
JAMA
|
2005
|
3.43
|
|
4
|
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2006
|
2.87
|
|
5
|
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
|
Clin Cancer Res
|
2001
|
2.53
|
|
6
|
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
|
J Clin Oncol
|
2004
|
2.49
|
|
7
|
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
|
Blood
|
2008
|
2.46
|
|
8
|
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
|
J Natl Cancer Inst
|
2006
|
2.34
|
|
9
|
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
|
J Clin Oncol
|
2007
|
2.20
|
|
10
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
Clin Cancer Res
|
2005
|
2.19
|
|
11
|
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2009
|
2.02
|
|
12
|
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
|
Blood
|
2006
|
1.74
|
|
13
|
Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.
|
J Thorac Cardiovasc Surg
|
2005
|
1.69
|
|
14
|
Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials.
|
Cancer
|
2002
|
1.68
|
|
15
|
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
|
Biol Blood Marrow Transplant
|
2006
|
1.63
|
|
16
|
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
|
Blood
|
2011
|
1.55
|
|
17
|
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
|
Leuk Lymphoma
|
2007
|
1.55
|
|
18
|
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study.
|
Cancer
|
2004
|
1.50
|
|
19
|
Recommendations for collection and handling of specimens from group breast cancer clinical trials.
|
J Clin Oncol
|
2008
|
1.50
|
|
20
|
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
|
J Natl Cancer Inst
|
2010
|
1.44
|
|
21
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
Blood
|
2010
|
1.41
|
|
22
|
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.
|
Cancer
|
2001
|
1.41
|
|
23
|
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
|
Leuk Lymphoma
|
2009
|
1.39
|
|
24
|
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
|
Urology
|
2003
|
1.32
|
|
25
|
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
|
J Clin Oncol
|
2005
|
1.29
|
|
26
|
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
|
Cancer
|
2010
|
1.23
|
|
27
|
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
|
Clin Cancer Res
|
2012
|
1.22
|
|
28
|
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
|
Blood
|
2004
|
1.20
|
|
29
|
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
|
Biol Blood Marrow Transplant
|
2011
|
1.12
|
|
30
|
Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.
|
J Thorac Oncol
|
2007
|
1.10
|
|
31
|
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
Oncologist
|
2010
|
1.10
|
|
32
|
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
|
Cancer
|
2005
|
1.09
|
|
33
|
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
|
Br J Haematol
|
2010
|
1.06
|
|
34
|
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
|
Leukemia
|
2011
|
1.05
|
|
35
|
Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.
|
Lung Cancer
|
2005
|
1.05
|
|
36
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
Cancer
|
2006
|
1.05
|
|
37
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.04
|
|
38
|
Auto-SCT for AML in second remission: CALGB study 9620.
|
Bone Marrow Transplant
|
2009
|
1.03
|
|
39
|
The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer.
|
Urology
|
2008
|
1.01
|
|
40
|
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
|
Ann Oncol
|
2009
|
1.01
|
|
41
|
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
|
Clin Cancer Res
|
2004
|
0.98
|
|
42
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
Cancer Chemother Pharmacol
|
2008
|
0.98
|
|
43
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
Cancer
|
2004
|
0.97
|
|
44
|
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
|
J Transl Med
|
2012
|
0.97
|
|
45
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
Clin Cancer Res
|
2007
|
0.96
|
|
46
|
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
|
Med Care
|
2008
|
0.96
|
|
47
|
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
|
Breast Cancer Res Treat
|
2006
|
0.95
|
|
48
|
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
|
J Clin Oncol
|
2003
|
0.95
|
|
49
|
Optimal management of malignant pleural effusions (results of CALGB 30102).
|
J Natl Compr Canc Netw
|
2012
|
0.95
|
|
50
|
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.
|
Psychooncology
|
2008
|
0.95
|
|
51
|
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
|
Clin Cancer Res
|
2011
|
0.94
|
|
52
|
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
|
Lung Cancer
|
2005
|
0.93
|
|
53
|
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
|
J Clin Oncol
|
2003
|
0.92
|
|
54
|
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
|
Clin Cancer Res
|
2005
|
0.92
|
|
55
|
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.
|
Ann Oncol
|
2011
|
0.90
|
|
56
|
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
|
Ann Oncol
|
2010
|
0.90
|
|
57
|
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
|
Ann Oncol
|
2008
|
0.90
|
|
58
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
J Thorac Oncol
|
2012
|
0.89
|
|
59
|
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.88
|
|
60
|
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
|
Cancer
|
2010
|
0.88
|
|
61
|
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
|
J Pain Symptom Manage
|
2011
|
0.88
|
|
62
|
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
|
Cancer
|
2006
|
0.87
|
|
63
|
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
J Thorac Oncol
|
2013
|
0.86
|
|
64
|
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
|
Cancer Treat Rev
|
2008
|
0.85
|
|
65
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
J Immunother
|
2005
|
0.84
|
|
66
|
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
|
Cancer
|
2011
|
0.84
|
|
67
|
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
|
J Thorac Oncol
|
2010
|
0.84
|
|
68
|
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
|
Urology
|
2008
|
0.83
|
|
69
|
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
|
J Thorac Oncol
|
2010
|
0.83
|
|
70
|
Overview of bladder cancer trials in the Cancer and Leukemia Group B.
|
Cancer
|
2003
|
0.83
|
|
71
|
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
|
Ann Oncol
|
2006
|
0.83
|
|
72
|
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
|
J Thorac Oncol
|
2008
|
0.81
|
|
73
|
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
|
Lung Cancer
|
2005
|
0.80
|
|
74
|
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.80
|
|
75
|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
|
Lung Cancer
|
2004
|
0.80
|
|
76
|
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
|
Pain Med
|
2012
|
0.80
|
|
77
|
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
|
J Thorac Oncol
|
2008
|
0.79
|
|
78
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
Leuk Res
|
2010
|
0.78
|
|
79
|
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
|
Br J Haematol
|
2008
|
0.78
|
|
80
|
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
|
Leuk Lymphoma
|
2006
|
0.77
|
|
81
|
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.77
|
|
82
|
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
|
J Thorac Oncol
|
2008
|
0.77
|
|
83
|
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
|
J Thorac Oncol
|
2009
|
0.76
|
|
84
|
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
|
Cancer
|
2001
|
0.76
|
|
85
|
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
|
Breast Cancer Res Treat
|
2008
|
0.76
|
|
86
|
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.
|
Ann Thorac Surg
|
2014
|
0.75
|
|
87
|
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
|
Semin Oncol
|
2008
|
0.75
|
|
88
|
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL).
|
J Clin Oncol
|
2004
|
0.75
|
|
89
|
Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405.
|
J Clin Oncol
|
2009
|
0.75
|
|
90
|
Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.
|
J Clin Oncol
|
2009
|
0.75
|
|
91
|
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.
|
Lung Cancer
|
2004
|
0.75
|
|
92
|
Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.
|
J Clin Oncol
|
2004
|
0.75
|